Europe Transdermal Drug Delivery System Market Forecast to 2030 - Regional Analysis - by Type, Application, and Distribution Channel

Description

List of Tables

The Europe transdermal drug delivery system market is expected to grow from US$ 10,433.86 million in 2022 to US$ 14,422.86 million by 2030. It is estimated to register a CAGR of 4.1% from 2022 to 2030.

Growing Demand for Noninvasive Drug Delivery Devices Fuels Europe Transdermal Drug Delivery System Market

Traditional drug delivery techniques such as intramuscular, intravenous, and rectal drug administration are not preferred by certain patient populations mainly due to the pain and complexities associated with them. With the improvements in medical science and definite drug delivery technologies, noninvasive drug delivery systems are now set to compete with the traditional method of injectable route of drug administration. The noninvasive drug delivery systems include drug delivery via oral; topical; transdermal-active (device-aided enhanced penetration) and transdermal-passive; and transocular membrane, transmucosal membrane, and alveolar membrane from inhaled medication. Transdermal drug delivery is advantageous in many ways over the oral route of administration. In particular, it evades the first-pass mechanism of the liver, which can otherwise impulsively metabolize drugs.

Further, transdermal delivery is not as painful as hypodermic injections, and this route leads to no dangerous medical waste and poses no risk of disease transmission by needle reuse, which is especially common in developing and under-developed countries. In addition, a noninvasive transdermal drug delivery system has simplified dosing schedules, and the drugs can be self-administered. Patient compliance is much higher when drugs are administrated noninvasively due to low or no pain involved. Therefore, this route is considered a preferred mode of drug delivery. Moreover, a non-invasive drug delivery system can significantly reduce the cost of clinical use because of the self-administration of the drugs by the patients. Thus, the advantages associated with a noninvasive drug delivery facilitated by transdermal drug delivery systems drive the market growth.

Europe Transdermal Drug Delivery System Market Overview

The Europe transdermal drug delivery system market is segmented into the UK, France, Germany, Spain, Italy, and the Rest of Europe. In 2022, the Germany held the largest share of the Europe transdermal drug delivery system market. The market is expected to grow significantly owing to the growing need for pain management and the increasing prevalence of cardiovascular diseases in the region. Cardiovascular diseases such as heart failure, myocardial infarction, coronary cardiac disease, and inflammatory heart disease account for the broadest health problems in the region. Germany is known for its advancement in technology that helps lead the country to the forefront in the medical and healthcare sectors. According to a study published in 2021 in the National Center for Biotechnology Information (NCBI), cardiovascular disease prevalence is often higher in East Germany. The country has also witnessed increasing innovations through market players in recent years. In May 2023, BioNxt Solutions Inc. received government approval to proceed with a comparative drug absorption study for a transdermal Rotigotine patch designed to treat Parkinson's disease. The company has R&D operations in North America and Europe, with an operational focus in Germany, and is currently undergoing regulatory approval and commercialization of medical products for European markets.

In March 2019, LTS Lohmann Therapie-Systeme AG and LEO Pharma A/S together started a clinical trial of microarray patches for the local intradermal treatment of psoriasis.

Germany is also among the primary countries that export healthcare products and services. In addition, the asset of technological advancement has set international standards for quality, safety, and reliability. Moreover, the German manufacturers and service providers in all health and medical segments fascinate foreign customers and partners by delivering healthcare innovation. Such developments in transdermal patches fuel the growth of the transdermal drug delivery system market in Germany.

Europe Transdermal Drug Delivery System Market Revenue and Forecast to 2030 (US$ Million)

Europe Transdermal Drug Delivery System Market Segmentation

The Europe transdermal drug delivery system market is segmented into type, application, distribution channel, and country.

Based on type, the Europe transdermal drug delivery system market is segmented into transdermal patches, transdermal gel, transdermal sprays, and others. The transdermal gel segment held the largest share of the Europe transdermal drug delivery system market in 2022. The transdermal patches is further sub segmented into drug-in-adhesive patches, matrix patches, reservoir membrane patches, and vapor patches.

In terms of application, the Europe transdermal drug delivery system market is categorized into cardiovascular diseases, central nervous system disorders, pain management, hormonal applications, and other applications. The pain management segment held the largest share of the Europe transdermal drug delivery system market in 2022. The pain management is further sub segmented into opioid and non-opioid. The hormonal applications is further sub segmented into transdermal estrogen & progesterone therapy and testosterone replacement.

By distribution channel, the Europe transdermal drug delivery system market is segmented into hospitals pharmacies, retail pharmacies, online pharmacies, and others. The hospitals pharmacies segment held the largest share of the Europe transdermal drug delivery system market in 2022.

Based on country, the Europe transdermal drug delivery system market is categorized into the UK, France, Germany, Spain, Italy, and the Rest of Europe. Germany dominated the Europe transdermal drug delivery system market in 2022.

Boehringer Ingelheim International GmbH, GSK Plc, Hisamitsu Pharmaceutical Co Inc, Johnson & Johnson, Lavipharm SA, Luye Pharma Group Ltd, Novartis AG, UCB SA, and Viatris Inc are some of the leading companies operating in the Europe transdermal drug delivery system market.

Product Code: TIPRE00013279

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Europe Transdermal Drug Delivery System Market - Key Industry Dynamics

4.1 Market Drivers
- 4.1.1 Increasing Prevalence of Chronic Diseases
- 4.1.2 Growing Demand for Noninvasive Drug Delivery Devices
- 4.1.3 High Demand for Self-Administration of Drugs
4.2 Market Restraints
- 4.2.1 Adverse Effects and Recall of Transdermal Drug Delivery Systems
4.3 Market Opportunities
- 4.3.1 Advancements in Smart Patches and 3D-Printed Patches
4.4 Future Trends
- 4.4.1 Strategic Initiatives by Manufacturers
4.5 Impact Analysis

5. Transdermal Drug Delivery System Market - Europe Market Analysis

5.1 Europe Transdermal Drug Delivery System Market Revenue (US$ Mn), 2022 - 2030

6. Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 - by Type

6.1 Overview
6.2 Europe Transdermal Drug Delivery System Market Revenue Share, by Type 2022 & 2030 (%)
6.3 Transdermal Patches
- 6.3.1 Overview
- 6.3.2 Transdermal Patches: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  - 6.3.2.1 Drug-in-Adhesive Patches
    - 6.3.2.1.1 Overview
    - 6.3.2.1.2 Drug-in-Adhesive Patches: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  - 6.3.2.2 Matrix Patches
    - 6.3.2.2.1 Overview
    - 6.3.2.2.2 Matrix Patches: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  - 6.3.2.3 Reservoir Membrane Patches
    - 6.3.2.3.1 Overview
    - 6.3.2.3.2 Reservoir Membrane Patches: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  - 6.3.2.4 Vapor Patches
    - 6.3.2.4.1 Overview
    - 6.3.2.4.2 Vapor Patches: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Transdermal Gels
- 6.4.1 Overview
- 6.4.2 Transdermal Gels: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
6.5 Transdermal Sprays
- 6.5.1 Overview
- 6.5.2 Transdermal Sprays: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
6.6 Others
- 6.6.1 Overview
- 6.6.2 Others: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)

7. Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 - by Application

7.1 Overview
7.2 Europe Transdermal Drug Delivery System Market Revenue Share, by Application 2022 & 2030 (%)
7.3 Cardiovascular Diseases
- 7.3.1 Overview
- 7.3.2 Cardiovascular Diseases: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Central Nervous System Disorders
- 7.4.1 Overview
- 7.4.2 Central Nervous System Disorders: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Pain Management
- 7.5.1 Overview
- 7.5.2 Pain Management: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  - 7.5.2.1 Opioid
    - 7.5.2.1.1 Overview
    - 7.5.2.1.2 Opioid: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  - 7.5.2.2 Non-Opioid
    - 7.5.2.2.1 Overview
    - 7.5.2.2.2 Non-Opioid: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
7.6 Hormonal Applications
- 7.6.1 Overview
- 7.6.2 Hormonal Applications: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  - 7.6.2.1 Transdermal Estrogen & Progesterone Therapy
    - 7.6.2.1.1 Overview
    - 7.6.2.1.2 Transdermal Estrogen & Progesterone Therapy: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  - 7.6.2.2 Testosterone Replacement
    - 7.6.2.2.1 Overview
    - 7.6.2.2.2 Testosterone Replacement: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
7.7 Other Application
- 7.7.1 Overview
- 7.7.2 Other Application: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)

8. Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 - by Distribution Channel

8.1 Overview
8.2 Europe Transdermal Drug Delivery System Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
8.3 Hospital Pharmacies
- 8.3.1 Overview
- 8.3.2 Hospital Pharmacies: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Retail Pharmacies
- 8.4.1 Overview
- 8.4.2 Retail Pharmacies: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Online Pharmacies
- 8.5.1 Overview
- 8.5.2 Online Pharmacies: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
8.6 Others
- 8.6.1 Overview
- 8.6.2 Others: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)

9. Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 - Country Analysis

9.1 Europe Transdermal Drug Delivery System Market
- 9.1.1 Europe Transdermal Drug Delivery System Market, by Country, 2022 & 2030 (%)
  - 9.1.1.1 Germany: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.1.1 Overview
    - 9.1.1.1.2 Germany: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.1.3 Germany: Europe Transdermal Drug Delivery System Market, by Type, 2020-2030 (US$ Million)
    - 9.1.1.1.3.1 Germany: Europe Transdermal Drug Delivery System Market, For Transdermal Patches by Type, 2020-2030 (US$ Million)
    - 9.1.1.1.4 Germany: Europe Transdermal Drug Delivery System Market, by Application, 2020-2030 (US$ Million)
    - 9.1.1.1.4.1 Germany: Europe Transdermal Drug Delivery System Market, For Pain Management by Application, 2020-2030 (US$ Million)
    - 9.1.1.1.4.2 Germany: Europe Transdermal Drug Delivery System Market, For Hormonal Applications by Application, 2020-2030 (US$ Million)
    - 9.1.1.1.5 Germany: Europe Transdermal Drug Delivery System Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.1.1.2 France: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.2.1 Overview
    - 9.1.1.2.2 France: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.2.3 France: Europe Transdermal Drug Delivery System Market, by Type, 2020-2030 (US$ Million)
    - 9.1.1.2.3.1 France: Europe Transdermal Drug Delivery System Market, For Transdermal Patches by Type, 2020-2030 (US$ Million)
    - 9.1.1.2.4 France: Europe Transdermal Drug Delivery System Market, by Application, 2020-2030 (US$ Million)
    - 9.1.1.2.4.1 France: Europe Transdermal Drug Delivery System Market, For Pain Management by Application, 2020-2030 (US$ Million)
    - 9.1.1.2.4.2 France: Europe Transdermal Drug Delivery System Market, For Hormonal Applications by Application, 2020-2030 (US$ Million)
    - 9.1.1.2.5 France: Europe Transdermal Drug Delivery System Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.1.1.3 UK: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.3.1 Overview
    - 9.1.1.3.2 UK: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.3.3 UK: Europe Transdermal Drug Delivery System Market, by Type, 2020-2030 (US$ Million)
    - 9.1.1.3.3.1 UK: Europe Transdermal Drug Delivery System Market, For Transdermal Patches by Type, 2020-2030 (US$ Million)
    - 9.1.1.3.4 UK: Europe Transdermal Drug Delivery System Market, by Application, 2020-2030 (US$ Million)
    - 9.1.1.3.4.1 UK: Europe Transdermal Drug Delivery System Market, For Pain Management by Application, 2020-2030 (US$ Million)
    - 9.1.1.3.4.2 UK: Europe Transdermal Drug Delivery System Market, For Hormonal Applications by Application, 2020-2030 (US$ Million)
    - 9.1.1.3.5 UK: Europe Transdermal Drug Delivery System Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.1.1.4 Italy: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.4.1 Overview
    - 9.1.1.4.2 Italy: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.4.3 Italy: Europe Transdermal Drug Delivery System Market, by Type, 2020-2030 (US$ Million)
    - 9.1.1.4.3.1 Italy: Europe Transdermal Drug Delivery System Market, For Transdermal Patches by Type, 2020-2030 (US$ Million)
    - 9.1.1.4.4 Italy: Europe Transdermal Drug Delivery System Market, by Application, 2020-2030 (US$ Million)
    - 9.1.1.4.4.1 Italy: Europe Transdermal Drug Delivery System Market, For Pain Management by Application, 2020-2030 (US$ Million)
    - 9.1.1.4.4.2 Italy: Europe Transdermal Drug Delivery System Market, For Hormonal Applications by Application, 2020-2030 (US$ Million)
    - 9.1.1.4.5 Italy: Europe Transdermal Drug Delivery System Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.1.1.5 Spain: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.5.1 Overview
    - 9.1.1.5.2 Spain: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.5.3 Spain: Europe Transdermal Drug Delivery System Market, by Type, 2020-2030 (US$ Million)
    - 9.1.1.5.3.1 Spain: Europe Transdermal Drug Delivery System Market, For Transdermal Patches by Type, 2020-2030 (US$ Million)
    - 9.1.1.5.4 Spain: Europe Transdermal Drug Delivery System Market, by Application, 2020-2030 (US$ Million)
    - 9.1.1.5.4.1 Spain: Europe Transdermal Drug Delivery System Market, For Pain Management by Application, 2020-2030 (US$ Million)
    - 9.1.1.5.4.2 Spain: Europe Transdermal Drug Delivery System Market, For Hormonal Applications by Application, 2020-2030 (US$ Million)
    - 9.1.1.5.5 Spain: Europe Transdermal Drug Delivery System Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.1.1.6 Rest of Europe: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.6.1 Overview
    - 9.1.1.6.2 Rest of Europe: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.6.3 Rest of Europe: Europe Transdermal Drug Delivery System Market, by Type, 2020-2030 (US$ Million)
    - 9.1.1.6.3.1 Rest of Europe: Europe Transdermal Drug Delivery System Market, For Transdermal Patches by Type, 2020-2030 (US$ Million)
    - 9.1.1.6.4 Rest of Europe: Europe Transdermal Drug Delivery System Market, by Application, 2020-2030 (US$ Million)
    - 9.1.1.6.4.1 Rest of Europe: Europe Transdermal Drug Delivery System Market, For Pain Management by Application, 2020-2030 (US$ Million)
    - 9.1.1.6.4.2 Rest of Europe: Europe Transdermal Drug Delivery System Market, For Hormonal Applications by Application, 2020-2030 (US$ Million)
    - 9.1.1.6.5 Rest of Europe: Europe Transdermal Drug Delivery System Market, by Distribution Channel, 2020-2030 (US$ Million)

10. Transdermal Drug Delivery System Market Industry Landscape

10.1 Overview
10.2 Growth Strategies in the Transdermal Drug Delivery System Market
10.3 Inorganic Growth Strategies
- 10.3.1 Overview
10.4 Organic Growth Strategies
- 10.4.1 Overview

11. Company Profiles

11.1 Novartis AG
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 Johnson & Johnson
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 GSK Plc
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Viatris Inc
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 Boehringer Ingelheim International GmbH
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Hisamitsu Pharmaceutical Co Inc
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Luye Pharma Group Ltd
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 Lavipharm SA
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments
11.9 UCB SA
- 11.9.1 Key Facts
- 11.9.2 Business Description
- 11.9.3 Products and Services
- 11.9.4 Financial Overview
- 11.9.5 SWOT Analysis
- 11.9.6 Key Developments

12. Appendix

12.1 About Us
12.2 Glossary of Terms